January 28, 2022
Sugarlogix Announces Relaunch as NAMUH
Company Will Close Nutritional Gap Between Infant Formula and Human MilkALAMEDA, Calif., Jan. 27, 2022 (GLOBE NEWSWIRE) — Sugarlogix, a…
Pharmaceuticals, Biotechnology and Life Sciences
Company Will Close Nutritional Gap Between Infant Formula and Human MilkALAMEDA, Calif., Jan. 27, 2022 (GLOBE NEWSWIRE) — Sugarlogix, a…
Financing led by SR One; Proceeds to advance proprietary IL-18 variant through Phase 2 clinical trial ST-067 is a first-in-class…
Submission supported by data from a Phase 3 bridging study of oliceridine injection compared to IV morphine, conducted in China…
Data to be presented suggests ACER-001 could represent a potential alternative to sodium and glycerol phenylbutyrate for treatment of UCDsNEWTON,…
SAN DIEGO, Jan. 27, 2022 (GLOBE NEWSWIRE) — Ensysce Biosciences, Inc. (“Ensysce” or the “Company”) (NASDAQ: ENSC, OTC: ENSCW), a…
Chinese Partner, 3D Medicines, Expects to Initiate Trial in Second Half of 2022 in Patients with Hematological Malignancies Who Achieved…
MELBOURNE, Australia, Jan. 26, 2022 (GLOBE NEWSWIRE) — Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the…
Mechelen, Belgium; 26 January 2022, 22.40 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) announced today that its supervisory board…
HOUSTON, Jan. 26, 2022 (GLOBE NEWSWIRE) — Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies…
CHARLESTON, S.C., Jan. 26, 2022 (GLOBE NEWSWIRE) — Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a…